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Abstract
Background: Infections remain a leading cause of morbidity and mortality among liver transplant (LT) recipients.
The aim of our study was to define the factors associated with outcome of early bacterial and fungal infections in a
cohort of patients who underwent LT at the University Hospital of Ancona over a nine year period.
Methods: All consecutive patients who underwent LT in our center were considered. An early infection was
defined as occurring in the first month post-transplantation.
Results: Among 330 patients who underwent LT from August 2005 to October 2014, 88 (27 %) had at least one
infection documented within 30 days after transplantation. In 54 cases only one site was involved, in 34 cases ≥2
sites. There were 43 (30 %) pneumonia, 40 (27 %) surgical site infections, 31 (22 %) blood stream infections, and 30
(21 %) urinary tract infections. Gram-negative bacteria accounted for 64 % of the culture-positive cases, followed by
Gram-positive bacteria (30 %) and fungi (6 %). A high proportion of drug-resistant strains was found within either
Gram-negative (79 %) or Gram-positive (81 %) bacteria. There were 27 out 88 patients (31 %) who died within 180 days
from the transplant. Factors independently associated with a higher risk of mortality were: renal replacement therapy
(HR 11.797 [CI95 % 3.082–45.152], p < 0.0001), multisite infections (HR 4.865 [CI95 % 1.417–16.700], p = 0.012) and being
infected with carbapenem-resistant Klebsiella pneumoniae (CRKP; HR 5.562 [CI95 % 1.186–26.088], p = 0.030).
Conclusions: Overall, these data indicate that early infections in LT patients are characterized by significant mortality. In
particular, an early infection caused by CRKP has an adverse impact on survival in these patients suggesting an urgent
need for adopting preventive measures to avoiding this complication.
Keywords: Liver transplantation, Early infections, Antibiotic resistance, Carbapenem-resistant Klebsiella pneumonaie,
Immunosuppression
Background
Infections remain a leading cause of morbidity and mor-
tality among liver transplant (LT) recipients [1]. Bacterial
infections are the most frequent type of infectious diseases
post-transplant, followed by fungal, viral and protozoal in-
fections [2]. A vast majority of bacterial infections occur
within the first month after transplantation and most of
these are caused by nosocomial organisms [3].
Accumulating data in the last several years has docu-
mented a shift towards increase in Gram-negative bacter-
ial infections and the emergence of multi-drug-resistant
(MDR) bacterial pathogens [4]. In particular, recent re-
ports that have investigated the impact of carbapenemase-
resistant- Klebsiella pneumonia (CRKP) in LT-recipients
have documented a mortality rate up to 70 % [5]. These
data underscore the importance of rigorous infection con-
trol practices to curtail the spread of resistant bacteria
which are particularly difficult to manage and are associ-
ated with poor outcomes in these patients.
The aim of our study was to analyze the factors re-
lated to outcome of bacterial and fungal infections in
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This was a retrospective, observational study conducted
at the Università Politecnica delle Marche, Ancona, Italy
from August 2005 to October 2014. The patient popula-
tion included all patients who underwent orthotopic LT
and who survived more than 48 h after transplantation.
The study group consisted of those patients who devel-
oped an early bacterial or fungal infection after LT.
Demographic, microbiological and clinical characteris-
tics, including preoperative, intraoperative and postoper-
ative recipient variables, were collected and 180-day
mortality from the transplant date was calculated. The
present research has been performed in accordance with
the ethical standards of the 1964 Declaration of Helsinki
and its later amendements. The Institutional Review
Board of the Azienda Ospedaliero-Universitaria Ospedali
Riuniti Umberto I°-Lancisi-Salesi granted retrospective
access to the data without need for individual informed
consent.
Definition and microbiology
An early infection was defined as that occurring in the
first month post-transplantation. Infections were identi-
fied through active surveillance in the LT ward, and
through reviews of outpatient medical records. The
criteria used for defining and classifying infections were
those proposed by the Centers for Disease Control and
Prevention [6]. In particular, the following were consid-
ered: pneumonia, surgical site infections (SSIs, including
deep intra-abdominal infections), blood stream infec-
tions (BSIs, including vascular catheter-related infec-
tions) and urinary tract infections (UTIs). Cultures for
the diagnosis of bacterial or fungal infection in blood,
sputum (or other respiratory secretions), urine or ascitic
fluid were obtained on the basis of clinical suspicion as
standard of care. Isolation of an organism from non-
sterile body sites such as drainage catheters in the ab-
sence of clinical signs of infection was considered
colonization. Microorganisms were cultured and identi-
fied according to standard bacteriological procedures.
Susceptibility testing of the strains to antibacterial agents
were performed by standard methods and the patterns
were reviewed and classified according to the ESCMID
(European Society for Clinical Microbiology & Infectious
Diseases) guidelines [7]. In particular, MDR was defined as
non-susceptibility to at least one agent in three or more
antimicrobial categories; XDR (extensively drug-resistant)
was defined as non-susceptibility to at least one agent
in all but two or fewer antimicrobial categories; PDR
(pandrug-resistant) was defined as non-susceptibility
to at all agents in all antimicrobial categories.
Statistical analysis
Patients were categorized into two subgroups based on
outcome (death or survival) at 180-day from the LT.
Quantitative data are depicted as median with interquar-
tile (Q1- Q3) ranges and compared by U Mann-Whitney
test. Qualitative variables were expressed as absolute and
relative frequencies. Categorical variables were com-
pared using the X2 test with Yates’ correction or Fisher’s
exact test when appropriate. The diagnostic accuracy of
selected risk factors was evaluated using receiver operat-
ing curve (ROC). We analyzed the factors associated
with mortality by using a stepwise binary logistic regres-
sion model in which variables found to be significant at
the univariate level (P-value <0.05) were introduced.
Statistical analysis was performed using SPSS software,
version 20 (Statistical Package for Social Sciences Inc.,
Chicago, IL).
Results
Among 330 LT patients considered in the study period,
88 (27 %) had at least one infection documented within
30 days after the transplant. Demographic and clinical
characteristics of these patients are reported in Table 1.
Median age was 53 years, male accounted for 80 % of the
population. The majority of the patients (66 %) underwent
LT due to a viral infection (HCV 56 % [49/88] and HBV
15 % [13/88]). There were 9 patients HIV-coinfected. The
type of anastomosis was termino-terminal in 89 % of
the patients. Twenty-three percent of the patients
underwent renal-replacement-therapy (RRT) in the
peri-operative period.
In 54 out of 88 (61 %) patients only one site was in-
volved while in 34 cases (39 %) ≥ 2 sites. A total of 144
infections were documented. There were 43 (49 %)
pneumonia, 40 (45 %) SSIs, 31 (35 %) BSIs and 30
(34 %) UTIs. Gram-negative bacteria accounted for 64 %
of the culture-positive cases, followed by Gram-positive
bacteria (30 %) and fungi (6 %). Polymicrobial and mixed
(bacterial plus fungal) infections occurred in 27 % and
7 % of the patients, respectively. Infections were due to
drug-resistant bacteria in 78 (89 %) of the patients.
Pathogens isolated in the study cohort are shown in
Table 2. Among Gram-negative bacteria, the most fre-
quently isolated pathogen was Klebsiella pneumoniae
(29 %) followed by Pseudomonas aeruginosa (22 %) and
Escherichia coli (21 %) while among Gram-positive
bacteria the most frequent organism was Enterococcus
faecium (57 %) followed by Staphylococcus aureus (19 %)
and Staphylococcus epidermidis (9 %).
Of 112 Gram-negative bacteria, 88 isolates (79 %) were
antibiotic resistant organisms and included 51 MDR and
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Table 1 Demographic and clinical characteristics of the study cohort
Characteristics All patients
n = 88, (%)
180-day outcome p value
Survival
n = 61 (%)
Death
n = 27 (%)
Age (years, ranges) 53 (34–67) 52 (34–66) 54 (37–67) 0.803
Gender Male 70 (80) 51 (84) 19 (70) 0.257
MELD score ≥25a 23 (26) 14 (23) 9 (33) 0.448
Child-Pugh stage C 42 (48) 27 (44) 15 (56) 0.436
Pre-LT hospitalizationb 18 (20) 10 (16) 8 (30) 0.257
Previous Abdominal Surgery 7 (8) 5 (8) 2 (7) 0.900
Indication for LT - Viralc 58 (66) 40 (66) 18 (67) 1.000
HCV positivity 49 (56) 35 (57) 14 (52) 0.804
HBs-Ag positivity 13 (15) 8 (13) 5 (18) 0.739
HIV positivity 9 (10) 5 (8) 4 (15) 0.448
Presence of HCCd 30 (34) 22 (36) 8 (30) 0.731
Type of anastomosis
Roux-en-y 10 (11) 6 (10) 4 (15) 0.488
Termino-terminal 78 (89) 55 (90) 23 (85)
RBC units≥ 5e 72 (82) 48 (79) 24 (89) 0.398
Plasma units≥ 10 39 (44) 26 (43) 13 (48) 0.804
RRTf 20 (23) 5 (8) 15 (56) <0.0001
Rejection 41 (47) 30 (49) 11 (41) 0.617
Diabetes 14 (16) 12 (20) 2 (7) 0.216
Multisite infectionsg 34 (39) 14 (23) 20 (74) <0.0001
Pneumonia 43 (49) 22 (36) 21 (78) 0.001
SSIsh 40 (45) 25 (41) 15 (56) 0.301
BSIsi 31 (35) 14 (23) 17 (63) 0.001
UTIsj 30 (34) 20 (33) 10 (37) 0.885
Gram-positive bacteria 45 (51) 29 (48) 16 (59) 0.434
Gram-negative bacteria 64 (73) 40 (66) 24 (89) 0.045
Polymicrobial infectionsk 24 (27) 11 (18) 13 (48) 0.008
Fungi 9 (10) 5 (8) 4 (15) 0.448
Mixed infectionsl 6 (7) 2 (3) 4 (15) 0.069
Overall resistant infectionsm 78 (89) 52 (85) 26 (96) 0.253
CRKP infectionsn 13 (15) 4 (7) 9 (33) 0.002
CMV infection 29 (33) 14 (23) 15 (56) 0.006
aMELD: Model for End-Stage Liver Disease
bPre-LT hospitalization: included any hospitalization within one month before LT
cIndication for LT included: viral [n = 58], alcoholic [n = 11], cryptogenetic [n = 7], cholestatic [n = 6], and other [n = 6] causes
dHCC: Hepato Cellular Carcinoma
eRBC: red blood cell units
fRRT: renal replacement therapy included: dialysis, continuous veno-venous haemo(dia)filtration and plasmapheresis
gMultisite infections: ≥ 2 sites (i.e.: blood and urine; blood and surgical sites etc.) were contemporarily involved
hSSIs: surgical sites infections
iBSIs: blood stream infections
jUTIs: urinary tract infections
kPolymicrobial infections: infections caused by both Gram-negative and Gram-positive bacteria
lMixed infections: infections caused by both bacterial and fungal pathogens
mOverall resistant infections: infections caused by a bacterial pathogen showing any resistant pattern (see for details Table 3)
nCRKP infections: infections caused by carbapenem-resistant Klebsiella pneumoniae strains
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two XDR. Within the former group of isolates there were
22 carbapenem-resistant K. pneumoniae (CRKP) and 7
extended-spectrum beta-lactamase-producing (ESBL) bac-
teria. Among 53 Gram-positive bacteria, there were 43
MDR isolates (81 %), including 5 methicillin-resistant S.
epidermidis (MRSE) and 4 methicillin-resistant S. aureus
(MRSA). Additionally, there were 2 vancomycin-resistant
Enterococcus (VRE) isolates one of which was also MDR.
Candida albicans was the most commonly isolated yeasts
(40 %) followed by Candida glabrata (30 %).
There were 27 out 88 patients (31 %) who died within
180 days from the transplant. The main cause of death
was an infectious complication in 67 % of the cases,
while vascular, neurological and other types of complica-
tions occurred, as main causes of death, in 19 %, 7 %
and 7 % of the cases, respectively. A significantly higher
proportion of patients who died within this time interval
underwent RRT (Table 1). Additionally, CMV infection,
pneumonia, BSIs and multisite infections were all associ-
ated with a significantly higher proportion of mortality.
Similarly, infections due to Gram-negative bacteria,
polymicrobial infections and infections caused by CRKP
were all associated with a significantly higher proportion
of mortality (Table 1).
Table 2 Pathogens isolated in the study cohort
Microorganismsa n° (%) Types of infectionb Susceptibility patterns (%)c
Pneumonia SSIs BSIs UTIs






P. aeruginosa 25 (22) 14 6 2 3 5 MDR (20)
14 R (56)
6 S (24)
E. coli 23 (21) 8 2 4 9 4 ESBL (17)
14 MDR (61)
5 S (22)
S. maltophilia 7 (6) 5 1 1 – 1 R (14)
6 S (86)
A. baumannii 4 (4) 3 – 1 – 1 MDR (25)
1 XDR (25)
2 R (50)




E. faecium 30 (57) 1 20 7 2 28 MDR (94)d
1 VRE (3)
1 R (3)
S. aureus 10 (19) 4 5 1 – 4 MRSA (40)
6 S (60)
S. epidermidis 5 (9) – 1 3 1 5 MRSE (100)
Other gram-pos. 8 (15) 3 3 – 2 6 MDR (75)
2 S (25)
C. albicans 4 (40) – 1 – 3 ND
C. glabrata 3 (30) – 2 1 – ND
C. tropicalis 2 (20) – – – 2 ND
C. dubliniensis 1 (10) – 1 – – ND
aOthers included: Gram negative bacteria, Enterobacter cloacae (n° 5), Enterobacter aerogenes (n° 1), Serratia marcescens (n°4), Klebsiella oxytoca (n° 2), Acinetobacter
iwoffii (n° 2), Acinetobacter junii (n°1), Haemophilus influenzae (n° 1), Citrobacter braaki (n° 1), Prevotella spp. (n° 1), Bacteroides uniformis (n° 1), Morganella morganii
(n° 1); Gram positive bacteria: Enterococcus faecalis (n° 2), Streptococcus pneumoniae (n° 2), Staphylococcus haemolyticus (n°2), Staphylococcus pseudointermedius
(n° 1), Staphylococcus spp. (n° 1)
bSSIs, surgical site infections; BSIs, blood stream infections; UTIs, urinary tract infections
cCRKP, carbapenem-resistant Klebsiella pneumoniae; ESBL, extended-spectrum beta-lactamase; XDR, extensive drug resistant; MDR, multi drug resistant; MRSA,
methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; VRE, vancomycin-resistant Enterococcus; R, resistance patterns not
included in previous definition; S, fully susceptible; -, none; ND, not done; d,there was one VRE strain within the 28 MDR
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In multivariate analysis, factors independently associated
with a higher risk of mortality were: RRT (HR 11.797
[CI95 % 3.082–45.152], p < 0.0001), multisite infections
(HR 4.865 [CI95 % 1.417–16.700], p = 0.012) and being
infected with CRKP (HR 5.562 [CI95 % 1.186–26.088],
p = 0.030) (Table 3).
Discussion
Solid organ transplant recipients are prone to healthcare-
associated infections [3]. Liver transplant recipients are
especially susceptible to bacterial infections as a result of
technical complexity of the surgical procedure and
complications related to abdominal surgery and manipula-
tion of the hepatobiliary system [1–3]. In this study we
evaluated the factors related to outcomes of early bacterial
and fungal infections in LT patients. Among 330 patients
transplanted over a nine year period, 88 (27 %) had at least
one infection documented within 30 days after the trans-
plant and 27 of them (31 %) died within 180 days from
the transplant. Although we investigated the contribution
of as many as 30 demographic, clinical and microbio-
logical characteristics, only three of these factors were in-
dependently associated with a higher risk of mortality.
These included RRT, multisite infections, and infection
due to CRKP.
Although only a minority of patients in our series (22/88)
underwent RRT during the intra- and peri-operative
period, this variable was significantly associated with a
negative outcome. Of note, the majority of our patients
undergoing this procedure were suffering from acute kid-
ney failure which is a known risk factor for higher mortality
in LT-recipients [8].
The type of infection per se did not influence sig-
nificantly the outcome. Pneumonia and BSIs, which
are generally characterized by negative outcomes in
immunocompromised patients, showed to be signifi-
cantly associated with high mortality rate at univariate
analysis while their effect was lost in the multivariate
model [9, 10]. Indeed multisite infections remained inde-
pendently associated with higher risk of mortality. This
can be due to the fact that involvement of two or more
sites is typical of sicker patients.
As a consequence of numerous hospitalizations, inva-
sive procedures, and frequent use of antibiotics LT,
patients accumulate risk factors for infections with drug-
resistant organisms [1–3]. In our series, almost 90 % of
the patients suffered from early infections caused by
drug-resistant bacteria. Importantly, we found that infec-
tion due to CRKP was one of the strongest predictor of
post-LT mortality. This finding agrees with that recently
reported by two studies showing that 1-year survival
dramatically dropped from 86 % to 29 % and from 93 %
to 55 % when LT patients were infected with CRKP
[11, 12]. Although several therapeutic approaches have
been experimented for CRKP infections including combin-
ation regimens which are usually associated with a lower
risk of mortality, the management of these infections is still
extremely difficult mainly in the immunocompromised
host [11–15]. Overall, these data suggest that in an
endemic area improved strategies for screening and pre-
vention of CRKP infections are urgently needed. One pro-
spective study conducted on 237 LT patients found that
RRT, mechanical ventilation >48 h, HCV recurrence and
colonization with CRKP at any time (i.e.: before and after
LT) were all independent risk factors for CRKP infections
[16]. Interestingly, based on these four variables the
authors developed a risk score able to discriminate patients
at low vs higher risk for CRKP infections [16]. Besides these
essential preventive strategies, it is crucial to introduce into
the market new effective antibiotics especially for those
patients, such as transplant-candidates and -recipients, in
which the presence of a difficult-to-treat bacterial infection
may either retard a life-saving procedure or worsen an
already fragile postoperative course.
The present study has several limitations. First, this
was a retrospective analysis. Although we tried to collect
as many clinical data as possible, we may have still
missed useful information for the management of LT-
patients. Second, we limited our observation to those in-
fections occurring within one month post-OLT. This
time interval was selected given that patients are at high-
est risk for infections during this period. Further studies
addressing the prevalence of infections over a longer
period of time post-OLT are ongoing in our center.
Third, since our data come from a single-center experi-
ence with LT recipients belonging to an area endemic
for CRKP, our findings may not be relevant to other pa-
tients populations.
Conclusion
In conclusion, these data indicate that early infections in
LT patients are characterized by significant mortality. In
particular, an early infection caused by CRKP has an ad-
verse impact on survival in these patients.
Table 3 Multivariate analysis of risk factors for 180-day mortality
of the study cohort
Risk factors Hazard ratio CI 95 % p value
Lower limit Upper limit
RRTa 11.797 3.082 45.152 <0.0001
Multisite infectionsb 4.865 1.417 16.700 0.012
CRKP infectionsc 5.562 1.186 26.088 0.030
aRRT: renal replacement therapy included: dialysis, continuous veno-venous
haemo(dia)filtration and plasmapheresis
bMultisite infections: ≥ 2 sites were contemporarily involved
cCRKP infections: infections caused by carbapenem-resistant Klebsiella
pneumoniae strains
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